941 related articles for article (PubMed ID: 18702732)
1. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
3. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice.
D'Astous M; Morissette M; Tanguay B; Callier S; Di Paolo T
Synapse; 2003 Jan; 47(1):10-4. PubMed ID: 12422368
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Liu LX; Chen WF; Xie JX; Wong MS
Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
[TBL] [Abstract][Full Text] [Related]
5. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Schmidt N; Ferger B
Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
[TBL] [Abstract][Full Text] [Related]
7. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
[TBL] [Abstract][Full Text] [Related]
8. Estrogen reduces BDNF level, but maintains dopaminergic cell density in the striatum of MPTP mouse model.
Tripanichkul W; Gerdprasert O; Jaroensuppaperch EO
Int J Neurosci; 2010 Jul; 120(7):489-95. PubMed ID: 20583901
[TBL] [Abstract][Full Text] [Related]
9. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
10. The synthetic ceramide analog L-PDMP partially protects striatal dopamine levels but does not promote dopamine neuron survival in murine models of parkinsonism.
Schneider JS; Bradbury KA; Anada Y; Inokuchi J; Anderson DW
Brain Res; 2006 Jul; 1099(1):199-205. PubMed ID: 16764837
[TBL] [Abstract][Full Text] [Related]
11. Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease.
Shchepinov MS; Chou VP; Pollock E; Langston JW; Cantor CR; Molinari RJ; Manning-Boğ AB
Toxicol Lett; 2011 Nov; 207(2):97-103. PubMed ID: 21906664
[TBL] [Abstract][Full Text] [Related]
12. Preventive role of PD-1 on MPTP-induced dopamine depletion in mice.
Jung HW; Son HY; Jin GZ; Park YK
Cell Biochem Funct; 2010 Apr; 28(3):217-23. PubMed ID: 20186864
[TBL] [Abstract][Full Text] [Related]
13. Fucoidan protects against dopaminergic neuron death in vivo and in vitro.
Luo D; Zhang Q; Wang H; Cui Y; Sun Z; Yang J; Zheng Y; Jia J; Yu F; Wang X; Wang X
Eur J Pharmacol; 2009 Sep; 617(1-3):33-40. PubMed ID: 19545563
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease.
Meuer K; Pitzer C; Teismann P; Krüger C; Göricke B; Laage R; Lingor P; Peters K; Schlachetzki JC; Kobayashi K; Dietz GP; Weber D; Ferger B; Schäbitz WR; Bach A; Schulz JB; Bähr M; Schneider A; Weishaupt JH
J Neurochem; 2006 May; 97(3):675-86. PubMed ID: 16573658
[TBL] [Abstract][Full Text] [Related]
16. Acupuncture inhibits microglial activation and inflammatory events in the MPTP-induced mouse model.
Kang JM; Park HJ; Choi YG; Choe IH; Park JH; Kim YS; Lim S
Brain Res; 2007 Feb; 1131(1):211-9. PubMed ID: 17173870
[TBL] [Abstract][Full Text] [Related]
17. Amiloride is neuroprotective in an MPTP model of Parkinson's disease.
Arias RL; Sung ML; Vasylyev D; Zhang MY; Albinson K; Kubek K; Kagan N; Beyer C; Lin Q; Dwyer JM; Zaleska MM; Bowlby MR; Dunlop J; Monaghan M
Neurobiol Dis; 2008 Sep; 31(3):334-41. PubMed ID: 18606547
[TBL] [Abstract][Full Text] [Related]
18. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
19. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum.
Kawasaki T; Ishihara K; Ago Y; Baba A; Matsuda T
J Pharmacol Exp Ther; 2007 Jul; 322(1):274-81. PubMed ID: 17429058
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson's disease.
Al-Sweidi S; Morissette M; Bourque M; Di Paolo T
Neuropharmacology; 2011 Sep; 61(4):583-91. PubMed ID: 21586296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
